Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...

Psilocybin therapy significantly decreased moderate to severe symptoms of depression in clinicians after frontline work ...

Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...

Innovative research to assess the effectiveness of digital and talking therapies for anxiety and depression has been given a ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

Depression is not just a mental health issue it’s a condition that affects the entire body and can accelerate the onset of ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Depression speeds up physical illness. A study shows adults with depression develop conditions 30% faster. Read more.

Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...

Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placeboSPN-820 was well-tolerated ...